Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript February 11, 2026Vanda Pharmaceuticals Inc. misses on earnings expectations.
Vanda Pharmaceuticals Inc. (VNDA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 2,750,000 | $19,002,500 | +38% | 2.59% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.15 | 10,000 | $41,500.00 | 2,335,731 | 2025-08-07 | Filing | |
| $4.39 | 481 | $2,111.59 | 2,325,731 | 2025-05-21 | Filing | |
| $4.40 | 9,519 | $41,883.60 | 2,325,250 | 2025-05-21 | Filing | |
| $4.22 | 20,000 | $84,472.00 | 2,315,731 | 2025-05-16 | Filing | |
| $5.01 | 5,000 | $25,050.00 | 2,295,731 | 2025-03-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.27 | 42,434 | $350,755.20 | 377,450 | 2026-03-02 | Filing | |
| $8.27 | 42,442 | $350,821.33 | 411,380 | 2026-03-02 | Filing | |
| $8.27 | 30,800 | $254,589.72 | 333,469 | 2026-03-02 | Filing | |
| $8.17 | 156,235 | $1,276,971.15 | 2,704,496 | 2026-03-02 | Filing | |
| $8.27 | 42,431 | $350,730.40 | 494,197 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 135,400 | $935,614 | 0% | |
| 2. | 117,502 | $811,939 | 0% | |
| 3. | 69,700 | $481,627 | 0% | |
| 4. | 63,878 | $441,397 | 0.05% | |
| 5. | 48,323 | $338,261 | 0% |
News See All
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript October 29, 2025Vanda Pharmaceuticals Inc. misses on earnings expectations.
22 Stocks on Jim Cramer’s Radar Recently
Cramer discussed that a number of major companies are struggling with limited supply, including Sandisk, Micron, and Boeing.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and thank you for standing by. My name is Argee, and I will be your conference operator today.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. At this time, I would like to welcome you to the Q3 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2024 Earnings Call Transcript
Operator: Thank you for standing by. My name is Hermine, and I will be your conference operator today. At this time, I would like to welcome everyone to Q1 2024 Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Jeannie and I will be your conference operator today. At this time, I would like to welcome everyone to the Q4 2023 Vanda Pharmaceuticals Inc.
Hedge Fund Resource Center